SCHEMBL19515212

SCHEMBL19515212

Cn1cc(-c2ccc3cnc(NC(=O)C4CCC(N5CCOCC5)CC4)cc3c2)cn1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 4)

geneUniProtsupporting neighboursconfidence
GSK3B P49841 19/20 1.00
DYRK1A Q13627 19/20 1.00
WNT1 P04628 13/20 1.00
ABL1 P00519 1/20 0.71

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23740712 1.00 GSK3B (1.00) GSK3BDYRK1AWNT1ABL1
SCHEMBL30004560 1.00 GSK3B (1.00) GSK3BDYRK1AWNT1ABL1
SCHEMBL30005658 1.00 GSK3B (1.00) GSK3BDYRK1AWNT1ABL1
SCHEMBL19515211 1.00 GSK3B (1.00) GSK3BDYRK1AWNT1ABL1
SCHEMBL19515756 1.00 GSK3B (1.00) GSK3BDYRK1AWNT1ABL1
SCHEMBL30005628 0.93 GSK3B (1.00) GSK3BDYRK1AWNT1ABL1
SCHEMBL19515684 0.93 GSK3B (1.00) GSK3BDYRK1AWNT1ABL1
SCHEMBL30004631 0.93 GSK3B (1.00) GSK3BDYRK1AWNT1
SCHEMBL19515623 0.93 GSK3B (1.00) GSK3BDYRK1AWNT1
SCHEMBL19515621 0.93 GSK3B (1.00) GSK3BDYRK1AWNT1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11673881-B2 Isoquinolin-3-yl carboxamides and preparation and use thereof BIOSPLICE THERAPEUTICS, INC. (US) 2023-06-13 US claimed
US-20230104155-A1 ISOQUINOLIN-3-YL CARBOXAMIDES AND PREPARATION AND USE THEREOF VICKERS-SPLICE CO-INVESTMENT LLC (KY) 2023-04-06 US claimed
EP-3943086-A1 ISOQUINOLIN-3-YL CARBOXAMIDES AND PREPARATION AND USE THEREOF BioSplice Therapeutics, Inc. (US) 2022-01-26 EP claimed
US-11174244-B2 Isoquinolin-3-yl carboxamides and preparation and use thereof BIOSPLICE THERAPEUTICS, INC. (US) 2021-11-16 US claimed
EP-3448838-B1 ISOQUINOLIN-3-YL CARBOXAMIDES AND PREPARATION AND USE THEREOF BIOSPLICE THERAPEUTICS INC (US) 2021-08-11 EP claimed
US-20200339536-A1 ISOQUINOLIN-3-YL CARBOXAMIDES AND PREPARATION AND USE THEREOF VICKERS VENTURE FUND VI PTE. LTD. (SG) 2020-10-29 US claimed
US-10508099-B2 Isoquinolin-3-yl carboxamides and preparation and use thereof SAMUMED, LLC (US) 2019-12-17 US claimed
US-20170313681-A1 ISOQUINOLIN-3-YL CARBOXAMIDES AND PREPARATION AND USE THEREOF VICKERS VENTURE FUND VI PTE. LTD. (SG) 2017-11-02 US claimed
US-11673881-B2 Isoquinolin-3-yl carboxamides and preparation and use thereof BIOSPLICE THERAPEUTICS, INC. (US) 2023-06-13 US disclosed
EP-3943086-A1 ISOQUINOLIN-3-YL CARBOXAMIDES AND PREPARATION AND USE THEREOF BioSplice Therapeutics, Inc. (US) 2022-01-26 EP disclosed
US-11174244-B2 Isoquinolin-3-yl carboxamides and preparation and use thereof BIOSPLICE THERAPEUTICS, INC. (US) 2021-11-16 US disclosed
EP-3448838-B1 ISOQUINOLIN-3-YL CARBOXAMIDES AND PREPARATION AND USE THEREOF BIOSPLICE THERAPEUTICS INC (US) 2021-08-11 EP disclosed
US-20200339536-A1 ISOQUINOLIN-3-YL CARBOXAMIDES AND PREPARATION AND USE THEREOF VICKERS VENTURE FUND VI PTE. LTD. (SG) 2020-10-29 US disclosed
US-10556885-B2 Isoquinolin-3-YL carboxamides and preparation and use thereof SAMUMED, LLC (US) 2020-02-11 US disclosed
US-10508099-B2 Isoquinolin-3-yl carboxamides and preparation and use thereof SAMUMED, LLC (US) 2019-12-17 US disclosed
US-10287267-B2 Isoquinolin-3-yl carboxamides and preparation and use thereof SAMUMED, LLC (US) 2019-05-14 US disclosed
US-20180222887-A1 ISOQUINOLIN-3-YL CARBOXAMIDES AND PREPARATION AND USE THEREOF VICKERS VENTURE FUND VI PTE. LTD. (SG) 2018-08-09 US disclosed
US-20180208580-A1 ISOQUINOLIN-3-YL CARBOXAMIDES AND PREPARATION AND USE THEREOF VICKERS VENTURE FUND VI PTE. LTD. (SG) 2018-07-26 US disclosed
US-20170313681-A1 ISOQUINOLIN-3-YL CARBOXAMIDES AND PREPARATION AND USE THEREOF VICKERS VENTURE FUND VI PTE. LTD. (SG) 2017-11-02 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180222887-A1 ISOQUINOLIN-3-YL CARBOXAMIDES AND PREPARATION AND USE THEREOF DYRK1A, DYRK3, DYRK1B GSK3B 10/4885DYRK1A 1/4885WNT1 7/4885
US-10556885-B2 Isoquinolin-3-YL carboxamides and preparation and use thereof DYRK1A, DYRK3, DYRK1B GSK3B 10/4885DYRK1A 1/4885WNT1 7/4885
US-20170313681-A1 ISOQUINOLIN-3-YL CARBOXAMIDES AND PREPARATION AND USE THEREOF DYRK1A, DYRK3, DYRK1B GSK3B 10/4885DYRK1A 1/4885WNT1 7/4885
US-11673881-B2 Isoquinolin-3-yl carboxamides and preparation and use thereof DYRK1A, DYRK3, DYRK1B GSK3B 10/4885DYRK1A 1/4885WNT1 7/4885
US-20200339536-A1 ISOQUINOLIN-3-YL CARBOXAMIDES AND PREPARATION AND USE THEREOF DYRK1A, DYRK3, DYRK1B GSK3B 10/4885DYRK1A 1/4885WNT1 7/4885
US-10508099-B2 Isoquinolin-3-yl carboxamides and preparation and use thereof DYRK1A, DYRK3, DYRK1B GSK3B 10/4885DYRK1A 1/4885WNT1 7/4885
US-10287267-B2 Isoquinolin-3-yl carboxamides and preparation and use thereof DYRK1A, DYRK3, DYRK1B GSK3B 10/4885DYRK1A 1/4885WNT1 7/4885
US-20230104155-A1 ISOQUINOLIN-3-YL CARBOXAMIDES AND PREPARATION AND USE THEREOF DYRK1A, DYRK3, DYRK1B GSK3B 10/4885DYRK1A 1/4885WNT1 7/4885
US-11174244-B2 Isoquinolin-3-yl carboxamides and preparation and use thereof DYRK1A, DYRK3, DYRK1B GSK3B 10/4885DYRK1A 1/4885WNT1 7/4885
US-20180208580-A1 ISOQUINOLIN-3-YL CARBOXAMIDES AND PREPARATION AND USE THEREOF DYRK1A, DYRK3, DYRK1B GSK3B 10/4885DYRK1A 1/4885WNT1 7/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.